CoCo in COPD treatment: evaluation of use, satisfaction and clinical effects

Completed

Conditions: Chronic Obstructive Pulmonary Disease
COPD
10006436

Registration Number: NL-OMON35348

Lead Sponsor: Revalidatiecentrum Het Roessingh

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 30

Inclusion Criteria

- a clinical diagnosis of COPD according to the GOLD criteria
- no exacerbation in the month prior to enrolment
- >=3 exacerbations or one hospitalization for respiratory problmens in the two years preceeding study entry
- (ex)smoker
- age>40 years
- post-bronchodilator FEV1 25-80% of predicted
- able to understand and read Dutch
- internet access at home

Exclusion Criteria

- serious other disease with a low survival rate
-other diseases influencing bronchial symptoms and/or lung function (e.g. cardiac insuficiency, sarcoidosis)
- severe psychiatric illness
- uncontrolled diabetes mellitus during a COPD exacerbation in the past or a hospitalization for diabetes mellitus in the two year preceding the study
- need for regular oxygen therapy (>16 h per day or pO2<7.2 kPa)
- maintenance therapy with antibiotics
- known alpha1-antitrypsine deficiency
- disorders or progressive disease seriously influencing daily activities (e.g. amputation, paralysis, progressive muscle disease)
- impaired hand function causing inability to use application

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The CoCo application will be evaluated among patients in terms of use of the<br /><br>application (registered by system), satisfaction with the application (UTAUT),<br /><br>satisfaction with received care (CSQ), and quality of care (RATER). </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Outcome measures to evaluate the clinical effects are: exacerbations (number,<br /><br>duration), amount of activity (accelerometer, BPAQ), exercise tolerance (6MWT),<br /><br>fatigue (MFI-20), health status and symptoms (CCQ), and quality of life<br /><br>(EQ-5D). </p><br>